FDA Approval of KEYTRUDA for Treatment of Gastric Cancer [transcript][audio]

Guest: Dr. Charles S. Fuchs, M.D.

Presenter: Neal Howard

Guest Bio: Charles S. Fuchs, MD, MPH, became Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on January 1, 2017. An internationally recognized expert in gastrointestinal cancers and cancer epidemiology, Dr. Fuchs was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health.

Segment Overview: Dr. Charles S. Fuchs discusses the recent FDA approval of KEYTRUDA (pembrolizumab) for patients with advanced gastric cancer that have received 2 or more lines of chemotherapy, and what this means for patients, doctors, and caregivers.

0 Comments

Leave a Reply

You must be logged in to post a comment.